Literature DB >> 34987067

Phenotyping of acute decompensated heart failure with preserved ejection fraction.

Yohei Sotomi1, Shungo Hikoso2, Sho Komukai3, Taiki Sato1, Bolrathanak Oeun1, Tetsuhisa Kitamura4, Akito Nakagawa5,6, Daisaku Nakatani1, Hiroya Mizuno1, Katsuki Okada1,7, Tomoharu Dohi1, Akihiro Sunaga1, Hirota Kida1, Masahiro Seo8, Masamichi Yano9, Takaharu Hayashi10, Yusuke Nakagawa11, Shunsuke Tamaki12, Tomohito Ohtani1, Yoshio Yasumura5, Takahisa Yamada8, Yasushi Sakata1.   

Abstract

OBJECTIVE: The pathophysiological heterogeneity of heart failure with preserved ejection fraction (HFpEF) makes the conventional 'one-size-fits-all' treatment approach difficult. We aimed to develop a stratification methodology to identify distinct subphenotypes of acute HFpEF using the latent class analysis.
METHODS: We established a prospective, multicentre registry of acute decompensated HFpEF. Primary candidates for latent class analysis were patient data on hospital admission (160 features). The patient subset was categorised based on enrolment period into a derivation cohort (2016-2018; n=623) and a validation cohort (2019-2020; n=472). After excluding features with significant missingness and high degree of correlation, 83 features were finally included in the analysis.
RESULTS: The analysis subclassified patients (derivation cohort) into 4 groups: group 1 (n=215, 34.5%), characterised by arrythmia triggering (especially atrial fibrillation) and a lower comorbidity burden; group 2 (n=77, 12.4%), with substantially elevated blood pressure and worse classical HFpEF echocardiographic features; group 3 (n=149, 23.9%), with the highest level of GGT and total bilirubin and frequent previous hospitalisation for HF and group 4 (n=182, 29.2%), with infection-triggered HF hospitalisation, high C reactive protein and worse nutritional status. The primary end point-a composite of all-cause death and HF readmission-significantly differed between the groups (log-rank p<0.001). These findings were consistent in the validation cohort.
CONCLUSIONS: This study indicated the feasibility of clinical application of the latent class analysis in a highly heterogeneous cohort of patients with acute HFpEF. Patients can be divided into 4 phenotypes with distinct patient characteristics and clinical outcomes. TRIAL REGISTRATION NUMBER: UMIN000021831. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  heart failure with preserved ejection fraction

Mesh:

Year:  2022        PMID: 34987067     DOI: 10.1136/heartjnl-2021-320270

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   7.365


  2 in total

1.  Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction.

Authors:  Bo Liang; Yi Liang; Ning Gu
Journal:  BMC Cardiovasc Disord       Date:  2022-06-10       Impact factor: 2.174

2.  Minimal subphenotyping model for acute heart failure with preserved ejection fraction.

Authors:  Yohei Sotomi; Taiki Sato; Shungo Hikoso; Sho Komukai; Bolrathanak Oeun; Tetsuhisa Kitamura; Daisaku Nakatani; Hiroya Mizuno; Katsuki Okada; Tomoharu Dohi; Akihiro Sunaga; Hirota Kida; Masahiro Seo; Masamichi Yano; Takaharu Hayashi; Akito Nakagawa; Yusuke Nakagawa; Shunsuke Tamaki; Tomohito Ohtani; Yoshio Yasumura; Takahisa Yamada; Yasushi Sakata
Journal:  ESC Heart Fail       Date:  2022-04-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.